In a joint interview, former Canadian Prime Minister Brian Mulroney and Acreage CEO Kevin Murphy discuss the global significance of Canada’s adult-use legalization, the business opportunities in medical cannabis, and when the MJ industry might see another major corporation enter the business after Constellation Brand’s $3.8 billion (CA$5 billion) investment in Canopy Growth.
A new report pegs Australia’s recreational cannabis market at 7.8 billion Australian dollars ($5.5 billion) – assuming a fully legal and regulated market is put in place by 2023.
Lithuania’s Parliament voted unanimously to give doctors the ability to prescribe marijuana to treat certain health conditions, making it the latest European Union country to approve the use of medical cannabis.
On the eve of Canada’s historic launch of its recreational marijuana program, the global cannabis industry appears poised for explosive growth thanks to the confluence of a host of market developments.
GW Pharmaceuticals is setting out to sell $300 million worth of U.S. depository shares.
Type CBD into a search engine and it will populate with new brand names every day, said Steve DeForest, the chief operating officer and chief compliance officer for Los Angeles-based Green Gorilla, a manufacturer and online retailer of hemp-derived CBD oils, topicals and pet products.
The U.S. Drug Enforcement Administration has taken some cannabidiol off the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic, cannabis-derived medicine to win federal approval.
It’s a decision that immediately affects CBD producers but also signals the agency’s first admission that the plant has medical value.
Investors are flocking to a U.S.-listed exchange-traded fund (ETF) that tracks nearly 40 Canadian and American cannabis firms.
